Nutrileads announces positive outcome proof of concept study in humans

Press release 24 november 2016
NUTRILEADS announces positive outcome proof of concept study in humans

NUTRILEADS B.V., a Dutch Nutrition & Health startup today announces the positive outcome of a proof of concept study in humans demonstrating that its lead ingredient IMPP-1 is safe, well tolerated and supports immune function in humans.

NUTRILEADS develops nutritional ingredients for application in health-promoting food products. The company was founded in 2012 based upon an invention originating from Unilever. In 2015, NutriLeads closed a successful seed financing round with an investor syndicate comprising Thuja Capital, DSM Venturing BV, PPM Oost and Shift Invest and is currently discussing a series A financing. 

NutriLeads' lead ingredient Immuno Modulatory Plant Polysaccharide-1 (IMPP-1) can be sustainably sourced from food crops. Nutrileads is developing this patented ingredient for different food applications including dietary supplements, medical food and functional food to reach various target populations.

The results of the first proof of concept study with IMPP-1 in healthy volunteers were evaluated by an international group of key opinion leaders from industry and academia. The experts concluded that the results demonstrate excellent tolerability and safety characteristics and significant and dose dependent stimulation of the immune system.

"The positive result in first proof of concept study in healthy volunteers provides the necessary confidence to go full speed ahead with our ambitious development program including several clinical trials to support the use of this proprietary ingredient from sustainable sources as dietary supplement and for application in specialized functional and medical food products" indicates Ruud Albers, PhD, CEO of NutriLeads.

 



Back


Share this article:

Contact us

Laan van Kronenburg 14
1183 AS Amstelveen
T 020 3032071
E info@shiftinvest.com
KvK: 61295922